Sign up to save your podcasts
Or
Share Eligibility for Anti-Amyloid Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eligibility for Anti-Amyloid Treatment
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
View all episodes
By American Academy of Neurology
4.7
279279 ratings
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
More shows like Neurology® Podcast
View all
JAMA Editors' Summary
135 Listeners
NEJM This Week
315 Listeners
Practical Neurology Podcast
47 Listeners
JAMA Clinical Reviews
495 Listeners
The Curbsiders Internal Medicine Podcast
3,321 Listeners
JAMA Medical News
90 Listeners
Core IM | Internal Medicine Podcast
1,108 Listeners
Neurology Today in 5
23 Listeners
Annals On Call Podcast
195 Listeners
The Clinical Problem Solvers
517 Listeners
Neurology Minute
131 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
366 Listeners
Continuum Audio
78 Listeners